Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $2,157,536.64 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 6,958 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $2,157,536.64. Following the transaction, the chief executive officer owned 85,662 shares in the company, valued at $26,562,072.96. This represents a 7.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, January 12th, Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $339.37 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock’s 50-day moving average is $368.11 and its two-hundred day moving average is $423.02. The firm has a market cap of $45.01 billion, a P/E ratio of 198.46 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the company posted ($0.65) EPS. The business’s revenue was up 84.9% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and kept a buy rating, signaling meaningful upside versus the current quote. Canaccord price-target raise
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target (~50% above the current level), providing a bullish benchmark for upside expectations. HC Wainwright note
• Positive Sentiment: Freedom Capital upgraded ALNY from Hold to Strong-Buy, adding to positive analyst momentum. Freedom Capital upgrade
• Positive Sentiment: Large institutional buying reported in Q4 (notable stake increases by Guggenheim, Caisse, Schonfeld and AQR) suggests strong institutional conviction and supports liquidity/demand for the shares.
• Neutral Sentiment: Short-interest entries in the feed show zero/NaN and a 0.0 days-to-cover figure — this looks like a data/reporting artifact rather than new shorting pressure; treat as non-actionable until exchange-confirmed data appears.
• Neutral Sentiment: Analysts collectively trimmed some near-term targets but still express confidence in 2026 growth — mixed model adjustments rather than a broad sell-off. Analysts trim targets
• Negative Sentiment: Several insiders sold shares this week, including CEO Yvonne Greenstreet (~6,958 shares) and multiple senior executives (Kevin Fitzgerald, Pushkal Garg, others). Large, clustered insider sales can weigh on sentiment even if they are routine or pre-planned. CEO sale SEC filing
• Negative Sentiment: Chardan trimmed its price target to $425 (a modest downgrade relative to some peers), and ALNY’s most recent quarterly report showed an EPS miss (Feb. 12) despite strong revenue growth — reminders of execution/near-term margin risk. Chardan target cut

Analyst Ratings Changes

A number of research firms recently issued reports on ALNY. Truist Financial lowered their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Chardan Capital decreased their target price on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Finally, Leerink Partners reduced their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV increased its holdings in Alnylam Pharmaceuticals by 2.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 11,786 shares of the biopharmaceutical company’s stock valued at $4,687,000 after buying an additional 302 shares during the period. Raymond James Financial Inc. boosted its position in shares of Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Raymond James Financial Inc. now owns 388,705 shares of the biopharmaceutical company’s stock valued at $154,432,000 after acquiring an additional 11,411 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $267,000. Mackenzie Financial Corp increased its stake in Alnylam Pharmaceuticals by 26.8% in the fourth quarter. Mackenzie Financial Corp now owns 12,395 shares of the biopharmaceutical company’s stock valued at $4,914,000 after acquiring an additional 2,622 shares during the period. Finally, Empowered Funds LLC lifted its stake in Alnylam Pharmaceuticals by 353.5% during the fourth quarter. Empowered Funds LLC now owns 19,431 shares of the biopharmaceutical company’s stock worth $7,727,000 after purchasing an additional 15,146 shares during the period. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.